4-Antibody to collaborate with HGS

Published: 16-Aug-2011
Ingredients Research & Development

To discover and develop fully human therapeutic antibodies


Swiss biopharmaceutical firm 4-Antibody has agreed a collaboration agreement with Human Genome Sciences (HGS) to discover and develop fully human therapeutic antibodies. Financial terms of the deal were not disclosed.

The partnership, initially involving two projects, will focus on 4-Antibody’s proprietary high throughput in vitro Retrocyte Display technology for rapid discovery of fully human antibodies against new targets nominated by HGS.

This is 4-Antibody’s second alliance with a pharmaceutical partner. The first was agreed with Boehringer Ingelheim in 2010.

Robert Burns, 4-Antibody’s ceo, said: ‘Collaborations serve an important role in validating our Retrocyte Display technology platform and we’re delighted that HGS wanted to enter into this multi-target collaboration with us. This adds an additional momentum to our other ongoing partnering activities.‘

See more

You may also like

Research & Development

4-Antibody to collaborate with Boehringer Ingelheim

Read more
Long-term collaboration for targets in various disease indications

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  5. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Research & Development

4-Antibody to collaborate with Boehringer Ingelheim

Long-term collaboration for targets in various disease indications
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Subscribe now